New therapeutic approaches in targeted therapy for renal cell carcinoma

**Poster Session 64**

**Monday, 27 March**

**12:15 - 13:45**

**Location:** Room Berlin, North Hall (Level 1)

**Chairs:** N. Kröger, Greifswald (DE)
A. Necchi, Milan (IT)
G. Stewart, Cambridge (GB)

**Aims and objectives of this session**
To discuss new therapeutic approaches based on basic research results.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

---

842

**Impact of intratumoral heterogeneity of renal cancer on drug response and development of resistance in patient derived xenografts**
By: Bedke J.¹, Flechsig S.², Hennenlotter J.¹, Wulf-Goldenberg A.², Jandrig A.³, Schostak M.³, Becker M.², Fichtner I.², Zeisig R.², Hoffmann J.², Schmees C.⁴, Stenzl A.¹
Institutes: University of Tübingen, Dept. of Urology and Renal Transplantation, Tübingen, Germany, ²EPO GmbH, Berlin-Buch, Berlin, Germany, ³University of Magdeburg, Dept. of Urology, Magdeburg, Germany, ⁴Natural and Medical Sciences Institute, Dept. of Molecular Biology, Reutlingen, Germany

843

**Pathological and prognostic significance of densities of CD57+ (natural killer cells), CD68+ (macrophage), and mast cells in renal cell carcinoma tissues**
By: Mochizuki Y., Miyata Y., Yasuda T., Nakamura Y., Matsuo T., Oba K., Sakai H.
Institutes: Nagasaki University Hospital, Dept. of Urology, Nagasaki, Japan

844

**A microplate co-culture assay allows individualised compound efficacy testing in patients derived 3D tumour spheroids and autologous immune cells**
By: Bedke J.¹, Bodenhöfer M.², Harland N.¹, Hennenlotter J.¹, Anderle N.², Schmees C.², Stenzl A.¹
Institutes: University of Tübingen, Dept. of Urology, Tübingen, Germany, ²Natural and Medical Sciences Institute At The University of Tübingen, Dept. of Molecular Biology, Reutlingen, Germany

845

**Enhanced RCC cell killing with natural killer cells generated from CD34+ hematopoietic progenitor cells combined with mAb cG250**
By: Oosterwijk-Wakka J.¹, Cany J.², Sabata Pérez H.¹, Dolstra H.², Mulders P.¹, Oosterwijk E.¹
Institutes: Radboudumc, Dept. of Urology, Nijmegen, The Netherlands, ²Radboudumc, Dept. of Hematology, Nijmegen, The Netherlands

846

**Orthotopic sunitinib resistant renal cell carcinoma xenograft mouse model**
By: Frees S., Moskalev I., Raven P., D’Costa N., Tan Z., Struss W., Chavez-Munoz C., So A.
Institutes: The Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada

847

**Inhibition of semaphorin 3C augments the anti-cancer effect of sunitinib in renal cancer**
By: Dejima T.¹, Takeuchi A.¹, Eto M.¹, Naito S.¹, Gleave M.², Ong C.²
Institutes: Kyushu University, Dept. of Urology, Fukuoka, Japan, ²The Vancouver Prostate Centre, Dept. of Urologic Sciences, Vancouver, Canada

848

**Expression pattern of immune checkpoint-associated molecules in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors**
By:
Targeting heat-shock protein 27 enhances sensitivity to sorafenib treatment in renal cancer in vitro and in vivo
Institutes: The Vancouver Prostate Centre, Dept. of Urology, Vancouver, Canada, University of Toronto, Dept. of Surgical Oncology, Toronto, Canada

Metformin drives synergistic effect and overcomes the treatment resistance of molecular targeted drugs for renal cell carcinoma
By: Matsumoto H., Mori J., Shimizu K., Fujii N., Kawai Y., Inoue R., Yamamoto Y., Hirata H., Shimabukuro T., Matsuyama H.
Institutes: Yamaguchi University, Graduate School of Medicine, Dept. of Urology, Ube, Japan

Panobinostat interacts with nelfinavir to inhibit renal cancer growth by causing endoplasmic reticulum stress
By: Okubo K., Sato A., Asano T., Isono M., Asano T.
Institutes: National Defense Medical College, Dept. of Urology, Tokorozawa, Japan

Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma
By: Abt D., Kraus M., Bader J., Besse A., Schmid H.-P., Engeler D.S., Driessen C., Besse L.
Institutes: Kantonsspital St. Gallen, Dept. of Urology, St. Gallen, Switzerland, Kantonsspital St. Gallen, Dept. of Medical Oncology and Hematology, St. Gallen, Switzerland

Ritonavir, a potent inhibitor of P-glycoprotein, enhances the anticancer effects of romidepsin in renal cancer cells
By: Sato A., Asano T., Okubo K., Isono M., Asano T.
Institutes: National Defense Medical College, Dept. of Urology, Tokorozawa, Japan

Transcriptomic-metabolomic profiling revealed that fatty acid oxidation-induced stress causes cancer cachexia
By: Fukawa T., Yan-Jiang B.C., Kanayama H.-O., Teh B.T., Shyh-Chang N.
Institutes: Tokushima University Graduate School, Dept. of Urology, Tokushima, Japan, Tokushima University Graduate School, Dept. Of Urology, Tokushima, Japan, National Cancer Centre Singapore, Laboratory of Cancer Epigenome, Singapore, Singapore, Genome Institute of Singapore, Agency For Science Technology and Research, Singapore, Singapore

Summary
G. Stewart, Cambridge (GB)